| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.35 | 0.02 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.02 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.02 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.076 | 0.02 |